Zhaoke Ophthalmology Pharmaceutical

Name

Zhaoke Ophthalmology Pharmaceutical

Legal name

Zhaoke Ophthalmology Limited

Website

https://www.zkoph.com

Company type

Public

Founded year

2016

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Ophthalmic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Ophthalmic Goods Manufacturing (339115)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

akta.pro secondary industries

Ophthalmology Pharmaceuticals (HLAIAAAL), Ophthalmic & Otic Generics (HLAIABAF), Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL), Rare Ophthalmology Disorder Therapies (HLAIAIAK)

Keywords

• Ophthalmic pharmaceuticals
• Eye disease therapeutics
• Prescription eye drops
• Generic ophthalmic drugs
• Ophthalmic drug manufacturing

Headquarters

HQ city

Hong Kong

HQ country

Hong Kong SAR China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Pharmaceutical Product Sales: Direct sales of proprietary and generic ophthalmic drugs including bimatoprost timolol (晶贝莹®), bimatoprost (晶贝清®), and other glaucoma medications through hospital and retail channels in China.
2. International Licensing and Distribution Agreements: Revenue from upfront payments, milestone payments, and royalty fees from international distribution partners for products like NVK002 (Korea, Indonesia, Thailand, Australia), BRIMOCHOL™ PF (Korea, Australia, New Zealand, Taiwan, Vietnam, Middle East), and cyclosporine ophthalmic gel (Indonesia, Middle East).
3. Medical Device Sales: Sales of medical devices including TONO-i tonometer for intraocular pressure measurement and 堡得视® thermal eye mask.
4. Technology Transfer and Licensing: Licensing out proprietary formulations and technology to international partners for development and commercialization in their territories.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

Zhaoke Ophthalmology is a vertically integrated ophthalmic pharmaceutical company that develops, manufactures, and commercializes a portfolio of innovative and generic drugs targeting six major eye diseases (dry eye, myopia, presbyopia, wAMD, DME, and glaucoma). Its 25 candidate drugs (13 innovative and 12 generic) are produced at a cGMP-compliant 7,600 sqm facility in Guangzhou Nansha and sold via hospital channels, e-commerce platforms, and international distribution partners.

Product overview

Zhaoke Ophthalmology Pharmaceutical is an ophthalmology pharmaceutical company with a comprehensive portfolio spanning innovative drugs and generic drugs covering six major eye disease areas: dry eye disease, myopia, presbyopia, wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and glaucoma. The portfolio consists of approximately 14 innovative drugs and 12 generic drugs, with manufacturing located at its advanced Nansha, Guangzhou facility. Key innovative drugs include Cyclosporin A Ophthalmic Gel (self-developed, once-daily dry eye treatment), NVK-002 (low-dose atropine for myopia control in children), BRIMOCHOL™ PF/Carbachol PF (pupil-modulating drops for presbyopia), TAB014 (bevacizumab-based antibody for wAMD), PAN-90806 (VEGFR2 inhibitor eye drop), ZKY001 (corneal repair peptide), and RGN-259. The generic portfolio centers on six glaucoma medications (Bimatoprost, Bimatoprost Timolol, Latanoprost, Travoprost, Latanoprost Timolol, Travoprost Timolol, Levobetaxolol), plus Epinastine HCl for allergic conjunctivitis. The company also commercializes a medical device, the TONO-i non-contact tonometer.

Differentiator

Problem solved

Functional benefit

Brands

• 晶贝莹® (Jingbeiying®): Brand name for bimatoprost timolol eye drops, a glaucoma medication launched in 2023
• 晶贝清® (Jingbeiqing®)
• 堡得视® (Baodeshi®)
• 睿保特
• 兆科博视
• YUVEZZI™

Products and services

• Bimatoprost Timolol Eye Drops (晶贝莹® / Jingbeiying®) Fixed-dose combination prostaglandin analog and β-blocker generic eye drops for glaucoma patients with inadequate response to monotherapy. Sold through hospital and retail channels in China.
• Bimatoprost Eye Drops (晶贝清® / Jingbeiqing®) Preservative-free single-dose prostaglandin analog generic eye drops for reducing intraocular pressure in open-angle glaucoma and ocular hypertension. China's first approved preservative-free single-dose bimatoprost generic.
• Latanoprost Eye Drops Prostaglandin analog (PGA) generic eye drop, one of the most frequently prescribed for open-angle glaucoma in China.
• Travoprost Eye Drops Prostaglandin analog (PGA) generic eye drop, one of the most commonly prescribed PGAs for open-angle glaucoma in China.
• Travoprost Timolol Eye Drops PGA and β-blocker combination generic eye drop targeting glaucoma.
• Latanoprost Timolol Eye Drops PGA and β-blocker combination generic eye drop for glaucoma. Completed Zhaoke's six-product glaucoma portfolio.
• Epinastine HCl Eye Drops (盐酸依匹斯汀滴眼液) Generic antihistamine/mast cell stabilizer eye drop for allergic conjunctivitis with dual mechanism; first-line therapy in China.
• TONO-i Tonometer Non-contact, portable tonometer for measuring intraocular pressure (IOP). Used without anesthesia, pain-free and infection-risk-free. Distributed under exclusive license from C&V Tech for Greater China, Thailand, and Malaysia.
• Baodeshi® (堡得视®) Thermal Eye Mask Thermal eye compress mask for dry eye and mild dry eye symptoms. Sold directly to consumers through e-commerce platforms.
• YUVEZZI™ (BRIMOCHOL™ PF) Preservative-free once-daily pupil-modulating eye drop (fixed-dose combination of carbachol and brimonidine tartrate) for correcting near vision loss associated with presbyopia. Licensed from Tenpoint Therapeutics for Greater China, South Korea, and Southeast Asia.

Quantifiable outcome

• Cyclosporine ophthalmic gel achieves efficacy similar to Restasis® with once-daily vs twice-daily dosing, with onset of action as early as 2 weeks vs 7-8 weeks for traditional formulations
• +4 more outcomes

Named customers10 records

Segments6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

27 partnerships are on record, tiered core and minor.

• Laboratório Teuto (Brazil)coreChannel Partner/ Reseller/ Distributor · 22 June 2026Strategic partnership signed at BIO 2026 for ophthalmology market entry into Brazil. Part of Hong Kong Science and Technology Parks (HKSTP) delegation partnership signing ceremony.
• PT. Erlangga Edi Laboratories (PT. Erela)coreChannel Partner/ Reseller/ Distributor · 5 June 2026Distribution and supply agreement for cyclosporine ophthalmic gel in Indonesia. Third strategic cooperation in Indonesia covering myopia, presbyopia, and dry eye. Indonesia's leading pharmaceutical company founded in 1965.
• 千寿制药株式会社 (Senju Pharmaceutical)coreChannel Partner/ Reseller/ Distributor · 26 January 2026Partnership for BRIMOCHOL™ PF commercialization in Vietnam. Japanese ophthalmology-focused pharmaceutical company headquartered in Osaka. Zhaoke's 8th BRIMOCHOL™ PF commercial partner.
• 东生华制药 (Dong Shenghua/Taiwan)coreChannel Partner/ Reseller/ Distributor · 8 December 2025Exclusive distribution partnership for BRIMOCHOL™ PF in Taiwan region. Taiwan Stock Exchange code 8432, focusing on cardiovascular, GI, CNS, and ophthalmology chronic disease treatments.
• PT Ferron Par PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 14 August 2025Distribution and supply agreement for NVK002 (atropine eye drops) in Indonesia. Second agreement signed November 2025 for BRIMOCHOL™ PF distribution. PT Ferron is top 15 Indonesian pharma company under Dexa Group.
• FAREVA GroupcoreStrategic or Co-development Partner · 15 July 2025Strategic partnership with French pharmaceutical CMO. Zhaoke becomes recommended partner for Chinese companies seeking pharmaceutical manufacturing. FAREVA has 13,000 employees, 41 production sites in 13 countries, EUR 2.22B revenue (2025).
• Jamjoom Pharmaceuticals Factory CompanycoreChannel Partner/ Reseller/ Distributor · 30 June 2025Exclusive supply and distribution agreement for cyclosporine ophthalmic gel in Middle East countries (Saudi Arabia, UAE, Bahrain, Kuwait, Oman, Qatar). Saudi Arabia-based pharmaceutical company founded in 2000 supporting Saudi Vision 2030.
• Somerset Therapeutics LLCcoreChannel Partner/ Reseller/ Distributor · 25 June 2025Strategic partnership for US market drug development, regulatory approval, and commercialization. Zhaoke to manufacture and supply drugs for US market commercialization.
• Lunatus Marketing & Consulting FZCOcoreChannel Partner/ Reseller/ Distributor · 14 April 2025Distribution and supply agreement for BRIMOCHOL™ PF in GCC countries (Saudi Arabia, UAE, Kuwait, Oman, Bahrain, Qatar). Dubai-based leading healthcare company bridging international companies to Middle East market.
• Interpharma Public Company LimitedcoreChannel Partner/ Reseller/ Distributor · 14 April 2025Partnership for promotion of atropine eye drops, BRIMOCHOL™ PF, and six glaucoma drugs in Thailand.
• AFT Pharmaceuticals LimitedcoreChannel Partner/ Reseller/ Distributor · 13 January 2025Distribution and supply agreement for BRIMOCHOL™ PF in Australia and New Zealand. Expanded in January 2026 to include Singapore. AFT is New Zealand multinational pharma operating across 125+ countries.
• 温州眼视光国际创新中心 (中国眼谷)coreStrategic or Co-development Partner · 3 June 2024Strategic partnership to establish 'China Eye Valley - Zhaoke Ophthalmology Innovation Drug Research Institute'. Focus on dry eye, myopia, presbyopia, wAMD, DME, and glaucoma research and development.
• Pharmaniaga Logistics Sdn. Bhd.coreChannel Partner/ Reseller/ Distributor · 5 March 2024Distribution and supply agreement for bimatoprost timolol (晶贝莹®) in Malaysia. Non-exclusive distribution with minimum purchase commitments and local trademark registration.
• 爱博诺德 (Aibo NuoDe)minorStrategic or Co-development Partner · 2 August 2023Strategic partnership for research, development, and commercialization of ophthalmic products. Joint promotion in hospital, clinic, and optometry center channels.
• Eyedetec MedicalminorChannel Partner/ Reseller/ Distributor · 8 June 2023Exclusive license, supply, and distribution agreement for Eye Lipid Mobilizer™ medical device for dry eye treatment.
• Kwangdong Pharmaceutical Co., Ltd.coreChannel Partner/ Reseller/ Distributor · 28 March 2023Exclusive distribution and supply agreement for NVK002 in South Korea. Second agreement signed January 2024 for BRIMOCHOL™ PF distribution in Korea. Kwangdong submitted BRIMOCHOL™ PF NDA to MFDS in November 2025.
• C&V TechminorChannel Partner/ Reseller/ Distributor · 9 November 2022Exclusive distribution agreement for TONO-i self-measuring intraocular pressure tonometer in Greater China, Thailand, and Malaysia. Device received NMPA medical device registration approval in August 2025.
• Visus Therapeutics Inc. (now merged as Tenpoint Therapeutics)coreOEM/ Whitelabel/ Licensing Partner · 11 May 2022Exclusive licensing agreement for BRIMOCHOL™ PF and Carbachol PF in Greater China, South Korea, and specified Southeast Asian countries. USD 15M upfront payment plus up to USD 115M in regulatory, commercialization and sales milestone payments plus tiered royalties.
• 国药控股分销中心/上药控股/华润医药商业coreChannel Partner/ Reseller/ Distributor · 8 March 2022Strategic cooperation agreements covering procurement, logistics management, market development, cooperation projects, and information communication. Leveraging their nationwide sales networks for product distribution.
• 东曜药业股份有限公司 (TOT BIOPHARM/East Optics)coreStrategic or Co-development Partner · 1 March 2022Supplement agreement signed March 2022 giving Zhaoke full control over TAB014 clinical trial execution and commercial decision-making rights for ophthalmic indications. East Optics continues to be responsible for TAB014 manufacturing for clinical and commercial use.
• Johns Hopkins University Wilmer Eye InstituteminorStrategic or Co-development Partner · 16 February 2022Corporate gift agreement supporting translational research and academic exchange at Wilmer Eye Institute. Zhaoke committed additional donations for sponsored research in subsequent two years.
• 开心生活科技 (HLT/医渡科技)minorStrategic or Co-development Partner · 16 December 2021Strategic cooperation for clinical research talent cultivation, clinical research network establishment, and digital clinical research model development using AI and big data technology.
• PharmaLogic Development Inc.minorImplementation/ SI/ Consulting Partner · 29 April 2021Regulatory consulting engagement to evaluate potential development of Asian pipeline products in North America. PharmaLogic has facilitated over 50 product approvals and has experience with FDA regulatory processes.
• NTC s.r.l.minorOEM/ Whitelabel/ Licensing Partner · 1 February 2021License and supply agreement for NTC010 (levofloxacin dexamethasone combination for cataract surgery) in China. Product already approved in 6 EU countries.
• PanOptica Inc.minorOEM/ Whitelabel/ Licensing Partner · 1 December 2020Exclusive license for PAN-90806 (VEGFR2 inhibitor for wAMD and DME) in Greater China, Korea, and specified Southeast Asian countries.
• Nevakar Inc./Vyluma Inc.coreOEM/ Whitelabel/ Licensing Partner · 9 October 2020Exclusive license for NVK002 (low-concentration atropine) in Greater China, South Korea, and Southeast Asian countries. Potential revenue of USD 102M upon achieving key regulatory and sales milestones plus royalties.
• IACTA Pharmaceuticals Inc.minorOEM/ Whitelabel/ Licensing Partner · 1 July 2020Exclusive license for IC-265 (Syk kinase inhibitor for dry eye/allergic conjunctivitis) and IC-270 (fixed-dose combination) in Greater China and Southeast Asian countries.

Scale indicators8 records

Recent moves7 records

Expansion highlights7 records

Broad incumbents

• Alcon: Global ophthalmology leader spanning pharmaceuticals, surgical, and vision care. Provides reference scale and global distribution benchmarks for Zhaoke's international ambitions even though it is far broader and far larger.
• AbbVie (Allergan Aesthetics/Eye Care): Owner of the legacy Allergan ophthalmology franchise including Lumigan (bimatoprost), Restasis (cyclosporine), and Ozurdex. Directly overlaps Zhaoke's key competitors in glaucoma and dry eye.
• Bausch + Lomb: Global ophthalmology player with both pharmaceutical (including glaucoma and dry eye) and surgical/vision care franchises. Relevant comparator for product portfolio breadth and competitive positioning versus Zhaoke's glaucoma generics.

Direct peers

• Senju Pharmaceutical: Japan-based ophthalmology-focused specialty pharmaceutical company. Comparable as a specialty ophthalmology drug developer and is itself a Zhaoke distribution partner for BRIMOCHOL PF in Vietnam, validating its position as a peer.
• Ocumension Therapeutics: Hong Kong-listed (HKEX 1477) Chinese ophthalmology specialty pharmaceutical company with a similar full-spectrum pipeline covering anterior and posterior segment diseases. Closest direct comp in geography, business model, and stage of commercialization.
• Ocular Therapeutix: US-listed ophthalmology specialty pharma developing innovative front- and back-of-eye therapeutics with a comparable pipeline-driven, pre-profitability model targeting similar indications including dry eye and presbyopia.
• Santen Pharmaceutical: Japan-headquartered global pure-play ophthalmology pharmaceutical company and the dominant Asia ophthalmology player. Most comparable specialty pharma reference for Zhaoke's pipeline strategy and global commercial ambition.
• Tenpoint Therapeutics: US-based ophthalmology specialty company formed via merger of Visus Therapeutics with Tenpoint; Zhaoke's licensor for BRIMOCHOL PF and Carbachol PF in Asia. Directly comparable as a presbyopia-focused ophthalmology innovator.

Others

• Lee's Pharmaceutical: Hong Kong-listed specialty pharmaceutical company founded by Dr. Benjamin Li (Zhaoke's founder/CEO) in 1994. Includes ophthalmology and other therapeutic areas; relevant as ecosystem/leadership lineage rather than a direct commercial competitor today.

Emerging players

• Tarsus Pharmaceuticals: US-listed emerging ophthalmology company with a first-in-class therapeutic (Xdemvy for Demodex blepharitis). Comparable as a late-stage commercial ophthalmology innovator adjacent to Zhaoke's specialty indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/zhaoke-ophthalmology

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zhaoke Ophthalmology Pharmaceutical